Professional Case Management Clinical Trials
Professional Case Management Clinical Trials is recorded as a service provider in 29 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 29 trials · Latest update first
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Adult Subjects with Classic Congenital Adrenal Hyperplasia
Sponsor Spruce Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available6 trial-level findings · Read insights
- The planned number of investigative sites was increased from 40 to 55.
- Weekly waking saliva collection was removed because of practical feasibility challenges and to reduce participant burden.
- Scheduled telephone contacts were reduced to lessen participant burden, while targeted as-needed contacts were retained or added for dose escalation, glucocorticoid tapering, safety monitoring, and compliance follow-up.
- COVID-19 mitigation measures allowed remote study visits and screening by telemedicine or at the participant's home where locally approved.
- Screening information collected within 45 days before Day 1 could be used when necessary, and screening data from the parallel SPR001-204 study could be transferred for eligibility determination.
- Eligibility criteria were revised to remove the elevated ACTH requirement, expand the acceptable glucocorticoid replacement range to 15-60 mg/day hydrocortisone equivalent, and update diagnostic and A4 requirements.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of mRNA 3210 in Participants with Phenylketonuria
Sponsor Moderna Therapeutics Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
Operational learnings available2 trial-level findings · Read insights
- One participant signed informed consent but did not receive investigational product and was screen failed.
- No treatment-emergent safety or efficacy data were generated or collected.
These findings describe the trial, not the service provider’s performance or responsibility.
A multicenter, open-label, prospective study to assess the concentration of bimekizumab in mature breast milk from mothers receiving treatment with Bimzelx® (bimekizumab)
Sponsor UCB Biopharma
- Start (EU)
- Not reported
- Latest update
- Estimated end
C5731006 - A PHASE 1B/2, OPEN-LABEL, MULTICOHORT STUDY OF DISITAMAB VEDOTIN IN ADULTS WITH HER2 EXPRESSING ADVANCED BREAST CANCER
Sponsor Pfizer Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Single-Arm, Open-Label Extension Study, Evaluating the Long-Term Safety and Clinical Efficacy of SAR447537 (INBRX-101) in Adults with Alpha-1 Antitrypsin Deficiency (AATD) Emphysema
Sponsor Sanofi AATD Inc.
- Start (EU)
- Latest update
- Estimated end
APOLLO: A Randomized, Double-Blind, Placebo-Controlled Study of Bitopertin to Evaluate the Efficacy, Safety, and Tolerability in Participants with Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
Sponsor Disc Medicine Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2, Open-Label, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Intravenous Doses of BMN 351 in Participants with Duchenne Muscular Dystrophy
Sponsor Biomarin Pharmaceutical Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3/3b, Randomized, Observer-blind, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Fluad and Fluad Quadrivalent Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age
Sponsor Seqirus UK Limited
- Start (EU)
- Latest update
- Estimated end
A Global, Phase 1/2, Open-label, Dose Optimization Study to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetics of mRNA-3927 in Participants with Propionic Acidemia
Sponsor Moderna Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Adenoassociated Virus Serotype 8-mediated Gene Transfer of Glucose-6-phosphatase in Patients With Glycogen Storage Disease Type Ia.
Sponsor Ultragenyx Pharmaceutical Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Reducing Supraphysiologic Glucocorticoid Use in Adult Subjects with Classic Congenital Adrenal Hyperplasia
Sponsor Spruce Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
I6T-MC-AMCE: A Phase 3b, Randomized, Multicenter, Controlled Study of Mirikizumab and Placebo or Mirikizumab Concomitantly Administered with Tirzepatide in Adult Participants with Moderately to Severely Active Crohn’s Disease and Obesity or Overweight
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
An Open-Label, Single-Arm, Phase 2 Study to Evaluate the Safety, Pharmacokinetics, and Biologic Activity of Pegcetacoplan in Pediatric Patients with Paroxysmal Nocturnal Hemoglobinuria
Sponsor Apellis Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
An Open-label Extension Study Evaluating the Long-term Safety and Efficacy of Seralutinib Orally Inhaled for the Treatment of Pulmonary Arterial Hypertension (PAH)
Sponsor GB002 Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Multinational, Open-label, Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9003 in Subjects with Limb Girdle Muscular Dystrophy 2E/R4 (EMERGENE)
Sponsor Sarepta Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
An Operationally Seamless Phase 1/2/3 Study Consisting of a Safety and Dose-finding Phase 1/2 and Randomized, Open-label, Active-controlled Phase 3 to Evaluate UX701 AAV Gene Therapy in Adults with Wilson Disease
Sponsor Ultragenyx Pharmaceutical Inc.
- Start (EU)
- Latest update
- Estimated end
Phase 2b randomized, double-blind, placebo-controlled crossover study evaluating the efficacy and safety of zagociguat in participants with MELAS (PRIZM)
Sponsor Tisento Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
An Open-label Study of the Safety, Pharmacokinetics, Efficacy, Pharmacodynamics, and Immunogenicity of Cipaglucosidase Alfa/Miglustat in Pediatric Subjects Aged 0 to < 18 Years with Late-onset Pompe Disease
Sponsor Amicus Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
VRDN-003-301: A phase 3, randomized, double-masked, placebo-controlled, efficacy, safety, and tolerability study of VRDN-003 in participants with active thyroid eye disease (TED)
Sponsor Viridian Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
VRDN-003-302: A phase 3, randomized, double-masked, placebo-controlled, efficacy, safety, and tolerability study of VRDN-003 in participants with chronic thyroid eye disease (TED)
Sponsor Viridian Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Professional Case Management Clinical Trials?
The 2026-10-09 snapshot links Professional Case Management Clinical Trials to 29 distinct CTIS trials. Recorded services include Home Health Care, Home Health, home health visits, Home Healthcare, among 19 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Professional Case Management Clinical Trials?
The most frequently recorded therapeutic areas are Genetic and Congenital Disorders, Metabolic Disorders, Dermatology, Musculoskeletal. Recorded phases include Phase 1, Phase 2, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Professional Case Management Clinical Trials conducted?
The linked trials record locations in 23 countries, including Spain, Germany, Italy, Netherlands, Denmark. These are trial locations, not confirmed office locations or countries where Professional Case Management Clinical Trials delivered services.
What can this page tell me about Professional Case Management Clinical Trials's trial experience?
Browse 29 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 2 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Professional Case Management Clinical Trials. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Professional Case Management Clinical Trials LLC